Logo image
Cervicovaginal safety of the formulated, biguanide-based human immunodeficiency virus type 1 (HIV-1) inhibitor NB325 in a murine model
Journal article   Open access

Cervicovaginal safety of the formulated, biguanide-based human immunodeficiency virus type 1 (HIV-1) inhibitor NB325 in a murine model

Karissa Lozenski, Tina Kish-Catalone, Vanessa Pirrone, Robert F Rando, Mohamed Labib, Brian Wigdahl and Fred C Krebs
Journal of biomedicine & biotechnology, v 2011, 941061
2011
PMID: 22131821
url
https://doi.org/10.1155/2011/941061View
Published, Version of Record (VoR) Open

Abstract

HIV-1 - drug effects Anti-HIV Agents - adverse effects Biguanides - administration & dosage Humans Biguanides - adverse effects Administration, Intravaginal Anti-HIV Agents - administration & dosage Animals Drug-Related Side Effects and Adverse Reactions Female HIV Infections - drug therapy Mice Disease Models, Animal
Vaginal microbicides that reduce or eliminate the risk of HIV-1 sexual transmission must do so safely without adversely affecting the integrity of the cervicovaginal epithelium. The present studies were performed to assess the safety of the biguanide-based antiviral compound NB325 in a formulation suitable for topical application. Experiments were performed using a mouse model of cervicovaginal microbicide application, which was previously shown to be predictive of topical agent toxicity revealed in microbicide clinical trials. Mice were exposed vaginally to unformulated NB325 or NB325 formulated in the hydroxyethyl cellulose "universal placebo." Following exposures to formulated 1% NB325 for 10 min to 24 h, the vaginal and cervical epithelia were generally intact, although some areas of minimal vaginal epithelial damage were noted. Although formulated NB325 appeared generally safe for application in these studies, the low but observable level of toxicity suggests the need for improvements in the compound and/or formulation.

Metrics

13 Record Views
3 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Biotechnology & Applied Microbiology
Medicine, Research & Experimental
Logo image